Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Shares Acquired by LS Investment Advisors LLC

LS Investment Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 32.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,817 shares of the company’s stock after acquiring an additional 2,628 shares during the period. LS Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $74,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. DNB Asset Management AS increased its position in shares of Teva Pharmaceutical Industries by 10.9% during the second quarter. DNB Asset Management AS now owns 85,262 shares of the company’s stock valued at $787,000 after acquiring an additional 8,379 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at about $76,000. Exane Derivatives increased its position in shares of Teva Pharmaceutical Industries by 470.2% during the second quarter. Exane Derivatives now owns 53,093 shares of the company’s stock valued at $490,000 after acquiring an additional 43,782 shares during the last quarter. Xact Kapitalforvaltning AB increased its position in shares of Teva Pharmaceutical Industries by 37.2% during the second quarter. Xact Kapitalforvaltning AB now owns 39,100 shares of the company’s stock valued at $361,000 after acquiring an additional 10,600 shares during the last quarter. Finally, Bridge Creek Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 9.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,425 shares of the company’s stock valued at $281,000 after acquiring an additional 2,600 shares during the last quarter. Institutional investors and hedge funds own 58.21% of the company’s stock.

Shares of TEVA stock opened at $9.30 on Friday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market capitalization of $9.32 billion, a P/E ratio of 3.32, a price-to-earnings-growth ratio of 0.89 and a beta of 1.73. The company has a 50 day moving average price of $7.51 and a 200 day moving average price of $8.90. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $6.07 and a fifty-two week high of $23.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company had revenue of $4.34 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The firm’s revenue was down 7.7% on a year-over-year basis. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.

TEVA has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating for the company. JPMorgan Chase & Co. dropped their price target on shares of Teva Pharmaceutical Industries from $9.00 to $7.00 and set an “underweight” rating for the company in a research report on Friday, September 6th. SunTrust Banks dropped their price target on shares of Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research report on Thursday, August 8th. Gabelli upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. Finally, BMO Capital Markets dropped their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating for the company in a research report on Friday, August 9th. Six research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $10.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Stock Symbol

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.